Resectable Pancreatic Cancer Clinical Trials

6 recruiting

Frequently Asked Questions

Common questions about Resectable Pancreatic Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 116 of 16 trials

Recruiting
Not Applicable

DCE-MRI Guided Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer

Borderline Resectable Pancreatic Cancer
Ohio State University50 enrolled2 locationsNCT06173310
Recruiting
Not Applicable

A Feasibility and Safety Study of Intratumoral Diffusing Alpha Radiation Emitters for the Treatment of Advanced Pancreatic Cancer

Pancreatic CancerMetastatic Pancreatic CancerPancreatic Adenocarcinoma+1 more
Alpha Tau Medical LTD.15 enrolled2 locationsNCT05657743
Recruiting
Not Applicable

Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer Emitters for the Treatment of Locally Advanced Pancreatic Cancer

Pancreatic CancerPancreatic AdenocarcinomaUnresectable Pancreatic Cancer
Alpha Tau Medical LTD.15 enrolled1 locationNCT06026943
Recruiting
Phase 2

Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer

Pancreas AdenocarcinomaResectable Pancreatic Cancer
Loma Linda University30 enrolled1 locationNCT03492671
Recruiting
Early Phase 1

A Single-Arm Investigator-Initiated Tria (IIT) Evaluating the Safety and Preliminary Efficacy of Autologous Drug-Loaded Neutrophils (NeuMed) in Patients With Unresectable Pancreatic Cancer

Unresectable Pancreatic Cancer
The First Affiliated Hospital of Air Force Medicial University3 enrolled1 locationNCT07198659
Recruiting
Phase 2

A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma

Pancreatic AdenocarcinomaResectable Pancreatic Cancer
Ashish Manne38 enrolled1 locationNCT05624918
Recruiting
Not Applicable

Predictive Risk Factors for Pancreatic Fistula After Pancreaticoduodenectomy

Pancreas CancerPancreas AdenocarcinomaPancreatic Fistula+4 more
Minia University100 enrolled1 locationNCT07022015
Recruiting
Phase 2

Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers

Unresectable Pancreatic CancerUnresectable Bile Duct CarcinomaUnresectable Biliary Tract Carcinoma
National Cancer Center, Korea98 enrolled1 locationNCT06135896
Recruiting
Phase 4

Efficacy of PERT for PEI in Unresectable Pancreatic Cancer.

Unresectable Pancreatic Cancer
Hospital Clinico Universitario de Santiago100 enrolled4 locationsNCT06099119
Recruiting
Phase 1Phase 2

Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer

Non-small Cell Lung CancerAdvanced Pancreatic AdenocarcinomaUnresectable Pancreatic Cancer+1 more
Dana-Farber Cancer Institute100 enrolled2 locationsNCT04789486
Recruiting

Comparative Study Between Immediate Surgery Versus Neoadjuvant Chemotherapy for Management of Resectable Pancreatic Cancer

SurgeryNeoadjuvant ChemotherapyResectable Pancreatic Cancer+1 more
Minia University30 enrolled1 locationNCT06978322
Recruiting

A New Clinical Pathway for Personalized Management of Borderline Resectable and Locally Advanced Pancreatic Cancer

Chemotherapy EffectLocally Advanced Pancreatic CancerPancreatectomy+1 more
Oslo University Hospital400 enrolled5 locationsNCT06944587
Recruiting
Phase 1

Safety and Efficacy of NRT6008 in Patients With Unresectable Locally Advanced Pancreatic Cancer (LAPC)

Unresectable Pancreatic Cancer
Chengdu New Radiomedicine Technology Co. LTD.58 enrolled6 locationsNCT06278454
Recruiting
Phase 3

NeoFOL-R Trial (Perioperative Versus Adjuvnat FOLFIRINOX in Resectable Pancreatic Cancer)

Neoadjuvant ChemotherapyResectable Pancreatic CancerEffects of Chemotherapy
Seoul National University Hospital609 enrolled2 locationsNCT05529940
Recruiting
Phase 2

Irinotecan Liposome II in Combination With 5-FU/LV and Oxaliplatin in Perioperative Treatment of Borderline Resectable Pancreatic Cancer

Borderline Resectable Pancreatic Cancer
Peking Union Medical College Hospital45 enrolled1 locationNCT06387810
Recruiting
Not Applicable

Implementing ctDNA and Circular DNA in Patients With Localized Pancreatic Cancer

Resectable Pancreatic Cancer
Copenhagen University Hospital at Herlev700 enrolled5 locationsNCT05788744